Driving a New Generation of Cell-based Medicines
Latest MaxCyte News
February 22 – February 24
Next Generation CAR-TCR
July 26, 2021
MaxCyte Announces Launch of Offering and Application to List on the Nasdaq Global Market
July 12, 2021
MaxCyte Announces Public Filing of Registration Statement with SEC for a Proposed Nasdaq Dual Listing
July 12, 2021
Financial information in the Form S-1 registration statement & Change to Board of Directors
June 15, 2021
MaxCyte Adds Two New Non-Executive Directors to Its Board
May 14, 2021
Proposed Dual-Listing on Nasdaq
February 23, 2021
MaxCyte to Participate in Two Upcoming Virtual Healthcare Investor Conferences
January 11, 2021
Myeloid Therapeutics and MaxCyte Enter Clinical and Commercial Licensing Agreement to Advance Myeloid’s Cell Therapy Programs
November 9, 2020
MaxCyte to Present at Two Upcoming Virtual Healthcare Investor Conferences
October 13, 2020
MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments
September 10, 2020
MaxCyte to Present at Upcoming 2020 H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference
September 9, 2020
MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer
June 25, 2020
MaxCyte® Initiates Launch of New ExPERT™ Range of Expanded Research and GMP Grade Disposables for Complex Cellular Engineering
June 22, 2020
MaxCyte to Present at 2020 European Biotech Investor Day
May 18, 2020
MaxCyte to Share Preliminary Phase I Data on MCY-M11 at ASCO 2020 Annual Meeting
May 7, 2020
Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement
April 9, 2020
MaxCyte Provides Business Update Related to COVID-19 Pandemic
April 6, 2020
MaxCyte to Present at Upcoming 2020 Solebury Trout Virtual Investor Conference
February 5, 2020
MaxCyte’s CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York
2020 Webinar Series
Flexible, clinically adaptable, non-viral approaches to CAR TCR methodologies
August 04, 2020 11:00 AM EDT
Scalable Manufacturing and Nanovesicle Delivery of CRISPR-Cas9 Ribonucleoproteins Using a cGMP- Compliant Cell Engineering Platform
September 17, 2020 8:00 AM PT
Dr. Mark DeWitt, a leading industry expert, shares his secrets on success with the development of a CRISPR/Cas9-based strategy
October 15, 2020 11:00 AM EDT
Webinars
Winning the Race: Decreasing Protein Development Timelines with Scalable Cell-Engineering
April 15, 2019
Latest Industry News
BIO CEO Defends Dr. Fauci, Says Criticisms “Undermine Our Response to this Pandemic”
In response to attacks on Dr. Anthony Fauci’s credibility and character, BIO President and CEO Dr. Michelle McMurry-Heath issued the following statement:”
July 16, 2020
A new biotechnology and pharmaceutical industry commitment to patients and the public.
January 8, 2020
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018.
February 25, 2019
BIO’s Workforce Development, Diversity & Inclusion Principles
MaxCyte has committed itself to fostering workplace development, diversity, and inclusion (WDDI) at MaxCyte and across the biotechnology industry. We are dedicated to being at the forefront of efforts to develop a diverse and talented global workforce. To that end, we affirmatively support the following WDDI Principles adopted by the Biotechnology Innovation Organization (BIO), and pledge to do our part to foster diversity and inclusion among our employees, customers, and patients.
February 6, 2018
BIO News: Champion the Biotechnology Industry
See BIO’s latest periodic updates on key issues facing the advancement of science and the ability of researchers and entrepreneurs to deliver the latest medical and biological breakthroughs to people who need them around the world.
July 26, 2017
BIO News: Saving Lives & Transforming Healthcare in the 21st Century
Learn about the impact of biotechnology on patients and society, as well as the factors needed to keep the innovation engine running strong.
April 7, 2017
Twitter Feed News
